Clarkston Consulting
Skip to content

2015 Life Sciences Trends Report

In 2015, life science companies will continue to find new avenues for decreasing costs, streamlining operations and improving shareholder value. Companies will maintain focus on therapies, technologies and investments that capitalize on their core business strengths, whether through partnerships or by divesting underperforming units. Commercialization and regulatory hurdles will remain a primary concern, particularly as generic & biologic drugs further penetrate world markets and governments and payers push for lower prices. A top priority for many life science companies is how to mitigate these challenges while also proving the value of their therapies to payers and patients.

To download our 2015 Life Sciences Trends Report, download the PDF below.